CD19 combined with CD22 or CD20 therapy is a promising immunotherapy approach for the treatment of hematological malignancies.
Dual-targeted CD19/CD22 CAR T and CD19/CD22 CAR T-cell therapy are currently being evaluated in clinical trials, and the extent of improvement using CD19 in combination with dual-targeted therapy has not yet been determined.
To compare the differences between the two in the treatment of hematological tumors, this study summarized the available evidence.
To evaluate and compare the efficacy and safety of CD19-combined CD22 and CD19-combined CD20 CAR T-cell therapy.
